Option-to-acquire deals remain rare in biotech's buzzy M&A season

J&J-Sail and AbbVie-Kestrel put a spotlight on the option-to-acquire structure — rare even in a record M&A year — with biotech and pharma leaders weighing its risk-sharing appeal against its wrinkles.

Raccontata daendpoints.news